Date:	2022/9/17	
Your Name:	Jing Zhao	
Manuscript Title:	Outcomes of ex	tended use of rh-endostatin in patients with advanced non-small cell lung cancer:
an analysis of a 10-y	ear retrospective	study
Manuscript number	(if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	T	Time frame: Since the initial	plaining of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
_	6 16 11 11	V N	
7	Support for attending meetings and/or travel	XNone	
	,		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
13	services Other financial or non-	V None	
13	financial interests	XNone	
	illialiciai liiterests		
Plea	ase summarize the above co	nflict of interest in the fol	owing box:
N	lone		

Date:	2022/9/17	
Your Name:	Yi Cheng	
Manuscript Title:	Outcomes of	extended use of rh-endostatin in patients with advanced non-small cell lung cancer:
an analysis of a 10-	year retrospectiv	e study
Manuscript numbe	r (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending	V Nana		
/	meetings and/or travel	XNone		
	ineetings and/or traver			Ī
	Detects also addisoned as	V. Naus		
8	Patents planned, issued or pending	XNone		
	pending			
9	Participation on a Data	X None		_
9	Safety Monitoring Board or	XNOTIE		H
	Advisory Board			-
10	Leadership or fiduciary role	X None		-
	in other board, society,			
	committee or advocacy			_
	group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other			
12	services	V N		
13	Other financial or non-	XNone		
	financial interests			_
Dlas	ase summarize the above co	affict of interest in the fall	owing hove	
Piec	ise suilillalize the above co	minut of interest in the foll	owing box.	
,	lone			
[]	ione			

Date:	2022/9/17	
Your Name:	Liting He	
Manuscript Title:	Outcomes of e	xtended use of rh-endostatin in patients with advanced non-small cell lung cancer:
an analysis of a 10-	year retrospective	study
Manuscript numbe	r (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	XNone	
	processing charges, etc.) No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X_None	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending	V Nana		
/	meetings and/or travel	XNone		
	ineetings and/or traver			Ī
	Detects also addisoned as	V. Naus		
8	Patents planned, issued or pending	XNone		
	pending			
9	Participation on a Data	X None		_
9	Safety Monitoring Board or	XNOTIE		H
	Advisory Board			-
10	Leadership or fiduciary role	X None		-
	in other board, society,			
	committee or advocacy			_
	group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other			
12	services	V N		
13	Other financial or non-	XNone		
	financial interests			_
Dlas	ase summarize the above co	affict of interest in the fall	owing hove	
Piec	ise suilillalize the above co	minut of interest in the foll	owing box.	
,	lone			
[]	ione			

Date:	2022/9/17	
Your Name:	Jianhua Wang	
Manuscript Title:	Outcomes of extended i	use of rh-endostatin in patients with advanced non-small cell lung cancer:
an analysis of a 10-y	ear retrospective study	
Manuscript number	(if known):	
-		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending	V Nana		
/	meetings and/or travel	XNone		
	ineetings and/or traver			Ī
	Detects also addisoned as	V. Naus		
8	Patents planned, issued or pending	XNone		
	pending			
9	Participation on a Data	X None		_
9	Safety Monitoring Board or	XNOTIE		H
	Advisory Board			-
10	Leadership or fiduciary role	X None		-
	in other board, society,			
	committee or advocacy			_
	group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other			
12	services	V N		
13	Other financial or non-	XNone		
	financial interests			_
Dlas	ase summarize the above co	affict of interest in the fall	owing hove	
Piec	ise suilillalize the above co	minut of interest in the foll	owing box.	
,	lone			
[]	ione			

Date:	2022/9/17	
Your Name:	Qingsong Xi	
Manuscript Title:	Outcomes of extended use of rh-endostatin in patients with advanced non-small cell lung cancel	:r:
an analysis of a 10-y	ar retrospective study	
Manuscript number	f known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial	planning of the work		
1	All support for the present	XNone			
	manuscript (e.g., funding,				
	provision of study materials,				
	medical writing, article				
	processing charges, etc.) No time limit for this item.				
	No time illinit for tims item.				
	Time frame: past 36 months				
2	Grants or contracts from	XNone			
	any entity (if not indicated				
	in item #1 above).				
3	Royalties or licenses	XNone			
4	Consulting fees	XNone			

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending	X None		_
,	meetings and/or travel	^_None		
	incettings and/or traver			Т
_	Detects planned issued as	V. Nana		
8	Patents planned, issued or pending	XNone		
	pending			_
9	Participation on a Data	X None		_
	Safety Monitoring Board or			-
	Advisory Board			H
10	Leadership or fiduciary role	X None		_
	in other board, society,			_
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other services			
13	Other financial or non-	X None		_
13	financial interests			
	interior interests			-
Plea	Please summarize the above conflict of interest in the following box:			
None				

Date:	2022/9/17	
Your Name:	Chen Gong	
Manuscript Title:	Outcomes of ex	tended use of rh-endostatin in patients with advanced non-small cell lung cancer:
an analysis of a 10-y	ear retrospective	study
Manuscript number	(if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial	planning of the work		
1	All support for the present	XNone			
	manuscript (e.g., funding,				
	provision of study materials,				
	medical writing, article				
	processing charges, etc.) No time limit for this item.				
	No time illinit for tims item.				
	Time frame: past 36 months				
2	Grants or contracts from	XNone			
	any entity (if not indicated				
	in item #1 above).				
3	Royalties or licenses	XNone			
4	Consulting fees	XNone			

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
7	Support for attending	X None		_
,	meetings and/or travel	^_None		
	incettings and/or traver			Т
_	Detects planned issued as	V. Nana		
8	Patents planned, issued or pending	XNone		
	pending			_
9	Participation on a Data	X None		_
	Safety Monitoring Board or			-
	Advisory Board			H
10	Leadership or fiduciary role	X None		_
	in other board, society,			_
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other services			
13	Other financial or non-	X None		_
13	financial interests			
	interior interests			-
Plea	Please summarize the above conflict of interest in the following box:			
None				